Sickle cell S-E disease

Sickle cell S-E disease (also known as hemoglobin SE disease or HbSE disease) is a rare hemoglobinopathy resulting from the co-inheritance of one hemoglobin S (HbS) allele and one hemoglobin E (HbE) allele. Hemoglobin S is caused by a specific mutation in the beta-globin gene (HBB) on chromosome 11, where glutamic acid is replaced by valine at position 6, while hemoglobin E results from a different mutation in the same gene, substituting glutamic acid with lysine at position 26. The combination of these two abnormal hemoglobins produces a compound heterozygous state that primarily affects the hematologic system. Clinically, sickle cell S-E disease is generally considered a milder sickling disorder compared to sickle cell disease (HbSS) or sickle cell S-C disease. However, affected individuals may still experience symptoms related to red blood cell sickling, including mild to moderate hemolytic anemia, episodes of vaso-occlusive pain crises, splenomegaly, and fatigue. The severity of symptoms can vary considerably among patients. Some individuals may remain largely asymptomatic, while others can develop complications such as splenic sequestration, acute chest syndrome, or other vaso-occlusive events, particularly under conditions of physiological stress such as dehydration, infection, hypoxia, or extreme temperatures. Management of sickle cell S-E disease follows general principles used for other sickle cell syndromes and is largely supportive. This includes adequate hydration, pain management during vaso-occlusive crises, folic acid supplementation, infection prevention with vaccinations and sometimes prophylactic antibiotics, and monitoring for organ damage. In more severe cases, hydroxyurea therapy may be considered to reduce the frequency of pain crises and acute complications. Blood transfusions may be necessary in cases of severe anemia or acute complications. Newborn screening programs that detect hemoglobin variants can identify affected individuals early, allowing for timely clinical follow-up and preventive care.

Common questions about Sickle cell S-E disease